Compound Detail
CHEMBL4297839
TIRZEPATIDE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL4297839 |
| Name | TIRZEPATIDE |
| Phase | Approved |
| Structure Type | SEQ |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
4
PK Parameters
0
Publications
9
Known Names
8
Indications
2
Mechanisms
Drug Information
| Molecule Type | Protein |
| First Approval | 2022 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Gastric inhibitory polypeptide receptor agonist | AGONIST | Gastric inhibitory polypeptide receptor | ✓ | ✓ |
| Glucagon-like peptide 1 receptor agonist | AGONIST | Glucagon-like peptide 1 receptor | ✓ | ✓ |
Indications
Diabetes Mellitus Diabetes Mellitus, Type 2 Obesity Overweight Non-alcoholic Fatty Liver Disease Obesity, Morbid Renal Insufficiency, Chronic Wolfram Syndrome
ATC Classification
A10BX16
tirzepatide
Level 1: ALIMENTARY TRACT AND METABOLISM
Level 2: DRUGS USED IN DIABETES
Drug Warnings
Black Box Warning
carcinogenicity
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 35123.0 | ng.hr.mL-1 | Canis lupus familiaris |
| Cmax | 0.344 | ug.mL-1 | Canis lupus familiaris |
| T1/2 | 93.8 | hr | Canis lupus familiaris |
| Tmax | 14.0 | hr | Canis lupus familiaris |
Data from ChEMBL 36 via Core Engine